374
Participants
Start Date
November 30, 2005
Primary Completion Date
March 31, 2008
Study Completion Date
March 31, 2008
P38 Inhibitor (4) 150mg
150mg po qd
P38 Inhibitor (4) 25mg
25mg po bid
P38 Inhibitor (4) 300mg
300mg po qd
P38 Inhibitor (4) 50mg
50mg po qd
P38 Inhibitor (4) 75mg
75mg po bid
Placebo
po bid
Dublin
Dublin
Johannesburg
Auckland
Fitzroy
Durban
Kippa-Ring
Caboolture
Lower Hutt
Cape Town
Christchurch
Bloemfontein
Tallinn
Tallinn
Athens
Berlin
New Hartford
Tallinn
Córdoba
Berlin
Rochester
A Coruña
Pittsburgh
Camp Hill
Wilkes-Barre
Norfolk
Lugo
Belmont
Madrid
Atlanta
Atlanta
Macon
Ormond Beach
Gainesville
Tamarac
Sarasota
Ocala
Birmingham
Knoxville
Memphis
Jackson
San Cristóbal de La Laguna
Guadalajara
Munster
South Bend
Traverse City
Monroe
Thessaloniki
Sioux Falls
North Fargo
Bad Nauheim
Monterrey
Wiesbaden
Wichita
Omaha
Heraklion
Tulsa
Carrollton
Bryan
San Luis Potosí City
Amarillo
Lubbock
München
Nampa
Paradise Valley
Tucson
Tucson
Tucson
Albuquerque
Erlangen
Upland
Escondido
Loma Linda
Riverside
Fair Oaks
Bend
Seattle
Everett
Erfurt
Worcester
Toms River
Curitiba
Goiânia
São Paulo
Edmonton
Winnipeg
St. John's
Mississauga
Ottawa
Toronto
Toronto
Pointe-Claire
Leipzig
Athens
Ioannina
Mexico City
Elblag
Sopot
Szczecin
Torun
Warsaw
Warsaw
Pretoria
Barcelona
Barcelona
Sabadell
Basingstoke
Cannock
Harrogate
Leeds
Metropolitan Borough of Wirral
Newcastle upon Tyne
Southampton
Wigan
Hoffmann-La Roche
INDUSTRY